A placebo-controlled randomized double-blind comparative study of AMG 0001 for obstructive arteriosclerosis

Trial Profile

A placebo-controlled randomized double-blind comparative study of AMG 0001 for obstructive arteriosclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Beperminogene perplasmid (Primary)
  • Indications Arteriosclerosis obliterans; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Sponsors AnGes MG
  • Most Recent Events

    • 22 Jan 2018 According to a AnGes MG media release, based on the data of this study, company submitted an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, for the treatment of critical limb ischemia (CLI), a severe condition of peripheral arterial disease.
    • 28 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top